Specifications
- Purity
- ≥98% (HPLC)
- Identity
- 1H-NMR
- Appearance
- Orange to red solid
Properties
- Solvents
- DMSO (10 mg/ml) or DMF (5 mg/ml).
Category: API's & Intermediates
Orantinib is an orally bioavailable receptor tyrosine kinase inhibitor. Orantinib binds to and inhibits the autophosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR), thereby inhibiting angiogenesis and cell proliferation. It is a potent ATP-competitive inhibitor of PDGFRβ, VEGFR2, and FGFR1 (IC50 = 0.06, 2.4, and 3.0 μM, respectively) but not EGFR (IC50 >100 μM). Orantinib suppresses tumor growth, blocks angiogenesis in tumors and induces apoptosis of tumor vasculature and regression of established tumors. Orantinib inhibits the phosphorylation of the stem cell factor receptor tyrosine kinase c-kit, often expressed in acute myelogenous leukemia cells, inhibits Aurora kinases B and C (IC50=35 and 210nM, respectively), and inhibits Unc-51-like serine/threonine kinase Ulk3, involved in hedgehog signaling. All together ornatinib exhibits antiangiogenic, anti-inflammatory, antimetastatic and proapoptotic activity.
Synonyms | TSU68, SU 6668, NSC 702827, 5-[1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-propanoic acid |
---|---|
Purity | ≥98% (HPLC) |
Appearance | Orange to red solid |
CAS-Number | 252916-29-3 |
Molecular Formula | C18H18N2O3 |
Molecular Weight | 310.35 |
Identity | 1H-NMR |
Solvents | DMSO (10 mg/ml) or DMF (5 mg/ml). |
Smiles | O=C1NC2=CC=CC=C2/C1=C/C3=C(C)C(CCC(O)=O)=C(C)N3 |
InChi Key | NHFDRBXTEDBWCZ-ZROIWOOFSA-N |
Shipping | AMBIENT |
Short Term Storage | -20°C |
Long Term Storage | -20°C |
Handling Advice | Protect from light and moisture. |
Use / Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Transportation | Not dangerous goods |
References | (1) L. Sun, et al., J. Med. Chem. 42, 5120 (1999), (2) A.D. Laird, et al., Cancer Res. 60, 4152 (2000), (3) B.D. Smolich, et al., Blood 97, 1413 (2001), (4) A.D. Laird, et al., FASEB J. 16, 681 (2002), (5) K. Godl, et al., Cancer Res. 65, 6919 (2005), (6) D.W. Kim, et al., J. Clin. Endocrinol. Metab. 91, 4070 (2006), (7) J. Bain, et al., Biochem. J. 408, 297 (2007), (8) M. Yamamoto, et al., Cancer Res. 68, 9754 (2008), (9) N. Kammasud, et al., Bioorg. Med. Chem. Lett. 19, 745 (2009), (10) A. Piirsoo, et al., Biochim. Biophys. Acta 1843, 703 (2014), (11) L. Kasak, et al., Biochem. 57, 5456 (2018) |
InChi | InChI=1S/C18H18N2O3/c1-10-12(7-8-17(21)22)11(2)19-16(10)9-14-13-5-3-4-6-15(13)20-18(14)23/h3-6,9,19H,7-8H2,1-2H3,(H,20,23)(H,21,22)/b14-9- |
Quantity | 25 mg, 100 mg, Bulk |